Kuehne+Nagel has announced it has agreed an international supply chain arrangement to provide distribution and storage of the Moderna COVID-19 vaccine. The deal includes distribution to markets in Europe, Asia, Middle East and Africa, and parts of the Americas.
This announcement follows the granting of conditional marketing authorisation by the European Medicines Agency (EMA) for COVID-19 Vaccine Moderna.
“We are proud to be partnering with Kuehne+Nagel from Europe to support the distribution of vaccines to global citizens. Following the recent approvals, this is another step closer to resolving the pandemic and an exciting time for both our companies and everyone involved,” Dan Staner, Vice President Head of EMEA region, Moderna Inc says.
The arrangement includes distribution and warehousing of the vaccine from Kuehne+Nagel’s pharma hub in Europe. Kuehne+Nagel will use its network of more than 230 operations worldwide to distribute the vaccine via road and air. In Europe alone, the company operates its own fleet of over 200 dedicated pharmaceutical transport vehicles. At all stages of transport and storage, product integrity at the required temperature of -20°C will be maintained.
Robert Coyle, Senior Vice President, Pharma & Healthcare, Kuehne + Nagel International AG, comments: “With today’s announcement, we take on the responsibility to distribute Covid-19 Vaccine Moderna around the world. We have invested in our pharma & healthcare network and our global team of experts for decades – we are ready now, for when it matters the most.”